MX2018016287A - Derivados de pirazolopirimidina como inhibidor de cinasa. - Google Patents

Derivados de pirazolopirimidina como inhibidor de cinasa.

Info

Publication number
MX2018016287A
MX2018016287A MX2018016287A MX2018016287A MX2018016287A MX 2018016287 A MX2018016287 A MX 2018016287A MX 2018016287 A MX2018016287 A MX 2018016287A MX 2018016287 A MX2018016287 A MX 2018016287A MX 2018016287 A MX2018016287 A MX 2018016287A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
pyrazolopyrimidine derivatives
present
pyrazolopyrimidine
derivatives
Prior art date
Application number
MX2018016287A
Other languages
English (en)
Inventor
Woo Kim In
Ah Jun Sun
Hee Lee Jun
Duck Kim Ji
Ryeong Han Mi
Yoo Jakyung
Ju Oh Yun
Youn Kim Nam
Seok Park Joon
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of MX2018016287A publication Critical patent/MX2018016287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención se refiere a un derivado de pirazolopirimidina, o a una sal farmacéuticamente aceptable del mismo. El compuesto de acuerdo con la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades que están asociadas con acciones inhibidoras de cinasas.
MX2018016287A 2016-06-30 2017-06-30 Derivados de pirazolopirimidina como inhibidor de cinasa. MX2018016287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160083050 2016-06-30
PCT/KR2017/006980 WO2018004306A1 (en) 2016-06-30 2017-06-30 Pyrazolopyrimidine derivatives as kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2018016287A true MX2018016287A (es) 2019-05-20

Family

ID=60785389

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009378A MX2021009378A (es) 2016-06-30 2017-06-30 Derivados de pirazolopirimidina como inhibidor de cinasa.
MX2018016287A MX2018016287A (es) 2016-06-30 2017-06-30 Derivados de pirazolopirimidina como inhibidor de cinasa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021009378A MX2021009378A (es) 2016-06-30 2017-06-30 Derivados de pirazolopirimidina como inhibidor de cinasa.

Country Status (22)

Country Link
US (1) US10961247B2 (es)
EP (2) EP3950691A1 (es)
JP (2) JP2019519579A (es)
KR (1) KR102329162B1 (es)
CN (2) CN113135920A (es)
AU (1) AU2017287762C1 (es)
BR (1) BR112018074621B1 (es)
CA (1) CA3025636C (es)
CL (1) CL2018003511A1 (es)
CO (1) CO2018013293A2 (es)
DO (1) DOP2018000275A (es)
EC (1) ECSP18093777A (es)
IL (1) IL263306B (es)
MX (2) MX2021009378A (es)
MY (1) MY191110A (es)
PE (1) PE20190811A1 (es)
PH (1) PH12018502507A1 (es)
RU (1) RU2714206C1 (es)
SA (2) SA518400547B1 (es)
SG (1) SG11201811470PA (es)
WO (1) WO2018004306A1 (es)
ZA (1) ZA201808431B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7098716B2 (ja) 2017-08-01 2022-07-11 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物
LT3733673T (lt) 2017-12-28 2022-08-10 Daewoong Pharmaceutical Co., Ltd. Oksi-fluorpiperidino darinys, kaip kinazės inhibitorius
KR102577241B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CN108586341B (zh) * 2018-05-25 2020-05-08 天津商业大学 酰胺类化合物和其药用盐及其制备方法和药物用途
EP3833350A4 (en) 2018-08-10 2022-05-18 Aclaris Therapeutics, Inc. PYRROLOPYRIMIDINE TKI INHIBITORS
US10851102B2 (en) 2019-01-23 2020-12-01 Theravance Biopharma R&D Ip, Llc Imidazole and triazole containing bicyclic compounds as JAK inhibitors
WO2020187267A1 (zh) * 2019-03-18 2020-09-24 上海海雁医药科技有限公司 Btk抑制剂及其药学上可接受的盐和多晶型物及其应用
CN110317176A (zh) * 2019-07-04 2019-10-11 沈阳药科大学 2-氨基嘧啶类化合物及其用途
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
CN113214265B (zh) * 2020-01-21 2023-07-07 江苏先声药业有限公司 嘧啶并五元环类化合物
WO2021147953A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
CN115023428A (zh) * 2020-01-21 2022-09-06 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN111620878A (zh) * 2020-06-10 2020-09-04 中国药科大学 吡咯并嘧啶类衍生物作为蛋白激酶抑制剂及其应用
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
WO2022062601A1 (zh) * 2020-09-22 2022-03-31 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023242597A1 (en) * 2022-06-16 2023-12-21 Amphista Therapeutics Limited Bifunctional molecules for targeted protein degradation
CN115368366A (zh) * 2022-08-02 2022-11-22 江苏省中医药研究院 嘧啶并吡唑类化合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
NZ535748A (en) 2002-04-12 2007-06-29 Pfizer Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
KR20080026654A (ko) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
EP2081435B1 (en) 2006-09-22 2016-05-04 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009026107A1 (en) * 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
WO2009054941A1 (en) 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
PE20091846A1 (es) * 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
EP3311818A3 (en) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
PE20130005A1 (es) 2009-12-01 2013-02-16 Abbvie Inc Compuestos triciclicos novedosos
BR112012033253A2 (pt) 2010-06-23 2016-11-22 Hanmi Science Co Ltd novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
WO2013041042A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Pyrazole carboxamides as janus kinase inhibitors
WO2013169401A1 (en) * 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2964647A1 (en) 2013-03-05 2016-01-13 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
CN117486865A (zh) 2013-07-11 2024-02-02 艾森医药公司 嘧啶衍生物作为激酶抑制剂
CN106065017B (zh) * 2013-09-18 2018-06-01 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
SI3318565T1 (sl) * 2013-12-05 2021-07-30 Pfizer Inc. Pirolo(2,3-D)pirimidinil, pirolo(2,3-B)pirazinil in pirolo(2,3-D)piridinil akrilamidi
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
CN105315285B (zh) * 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
KR101710127B1 (ko) 2014-08-29 2017-02-27 한화제약주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
CN105732637B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3778604A1 (en) 2015-02-13 2021-02-17 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same

Also Published As

Publication number Publication date
CO2018013293A2 (es) 2018-12-14
EP3478687B1 (en) 2024-03-20
EP3478687A1 (en) 2019-05-08
EP3950691A1 (en) 2022-02-09
US20200317673A1 (en) 2020-10-08
EP3478687A4 (en) 2020-02-19
JP7084961B2 (ja) 2022-06-15
CA3025636A1 (en) 2018-01-04
RU2714206C1 (ru) 2020-02-13
KR102329162B1 (ko) 2021-11-22
NZ748746A (en) 2020-08-28
CN109311896A (zh) 2019-02-05
CN109311896B (zh) 2021-08-24
PE20190811A1 (es) 2019-06-13
SG11201811470PA (en) 2019-01-30
DOP2018000275A (es) 2018-10-31
AU2017287762B2 (en) 2019-09-26
IL263306B (en) 2021-05-31
PH12018502507A1 (en) 2019-07-08
JP2019519579A (ja) 2019-07-11
CN113135920A (zh) 2021-07-20
ZA201808431B (en) 2020-05-27
CL2018003511A1 (es) 2019-04-05
CA3025636C (en) 2022-10-18
ECSP18093777A (es) 2018-12-31
BR112018074621B1 (pt) 2021-06-08
JP2020143162A (ja) 2020-09-10
BR112018074621A2 (pt) 2019-03-06
AU2017287762A1 (en) 2018-12-13
AU2017287762C1 (en) 2020-04-23
MY191110A (en) 2022-05-30
MX2021009378A (es) 2022-06-29
US10961247B2 (en) 2021-03-30
SA521430937B1 (ar) 2022-12-25
WO2018004306A1 (en) 2018-01-04
KR20180003472A (ko) 2018-01-09
SA518400547B1 (ar) 2022-09-20
IL263306A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
PH12019500480A1 (en) Pyridine compound
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
MX2017000450A (es) Compuestos terapeuticos inhibidores.
MX2017013797A (es) Inhibidor de janus quinasa.
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MY193239A (en) Novel b-lactamase inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
MX2017007655A (es) Compuestos para tratar el cancer.